Genitourinary Cancer | Norton Healthcare

Indication: Genitourinary Cancer

MK6482-013: Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma

Sub-indication: Genitourinary Cancer

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Merck Sharp & Dohme CORP

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.